OncLive

Articles

OncLive and the Ruesch Center for the Cure of Gastrointestinal Cancers Announce Recipients of the 2024 Luminary Awards in GI Cancers

October 9th 2024

OncLive and the Ruesch Center for the Cure of GI Cancers announce the winners of the 2024 Luminary Awards in GI Cancers.

Managing Patients With Breast Cancer on T-DM1 Therapy

January 14th 2022

The types of conversations that breast oncologists should have with their patients with breast cancer before initiating T-DM1, and recommendations for managing treatment-related adverse events.

Approaches to Monitoring Patients With Differentiated Thyroid Cancer

January 14th 2022

Marcia Brose, MD, PhD, FASCO, explains how she counsels and monitors patients with differentiated thyroid cancer and indicators to initiate therapy.

Adjuvant T-DM1 Therapy for HER2+ Breast Cancer

January 14th 2022

Impressions regarding the management of a 62-year-old woman with HER2-postive breast cancer who received adjuvant T-DM1 treatment following neoadjuvant TCHP and has signs of residual disease.

Thyrotropin Suppression for Differentiated Thyroid Cancer

January 14th 2022

The pros and cons of thyrotropin suppression as treatment for patients with differentiated thyroid cancer.

Establishing Treatment Goals and Monitoring Patients With DTC

January 7th 2022

Criteria used by endocrinologists/oncologists to establish goals of therapy for patients with differentiated thyroid cancer, and recommendations for active surveillance.

ADC Treatment Options and Clinical Data in Breast Cancer

January 7th 2022

An overview of antibody-drug conjugate therapies available for patients with metastatic breast cancer and triple-negative breast cancer based on outcomes demonstrated in clinical trials.

Molecular Testing Approaches for RAI-Refractory DTC

January 7th 2022

Marcia Brose, MD, PhD, FASCO, and Maria E. Cabanillas, MD, compare the use of molecular testing for radioactive iodine-refractory differentiated thyroid cancer at their institutions and highlight predictive and prognostic biomarkers.

Antibody-Drug Conjugate Therapy in Metastatic Breast Cancer

December 23rd 2021

Allison Butts, PharmD, BCOP, describes what antibody-drug conjugates are and explains the role in metastatic breast cancer treatment.

The HER2+ MBC Treatment Pipeline

December 22nd 2021

Exciting therapeutic strategies in the HER2-positive metastatic breast cancer space that demonstrate potential in addressing gaps in treatment.

Understanding HER2 Expression in Metastatic Breast Cancer

December 22nd 2021

A small panel of breast oncologists recognize growing interest in understanding the role of HER2 expression in metastatic breast cancer.

Changing Treatment Paradigms in HER2+ MBC

December 22nd 2021

Expectations regarding future treatment guidelines in HER2-positive metastatic breast cancer as a result of therapeutic advances.

RAI-Refractory Differentiated Thyroid Cancer

December 17th 2021

The typical diagnostic work-up for patients with advanced differentiated thyroid cancer, the rationale for treating patients with radioactive iodine (RAI), and a definition of RAI-refractory disease.

Diagnostic Criteria Used in Differentiated Thyroid Cancer

December 17th 2021

Signs and symptoms of differentiated thyroid cancer and recommendations for establishing an accurate diagnosis.

Thyroid Cancer Risk Factors

December 17th 2021

Naifa L. Busaidy, MD, FACP, FACE, comments on risk factors associated with the subtypes of thyroid cancers.

Classifying Thyroid Cancer

December 17th 2021

Giuseppe Barbesino, MD, highlights the various types of thyroid cancers and comments on how their differences impact management.

Second-Line Treatment for HER2+ MBC

December 15th 2021

Variables that affect second-line treatment decisions in HER2-positive metastatic breast cancer.

Treating After T-DM1 in Relapsed/Refractory HER2+ MBC

December 15th 2021

Recommendations regarding how to best treat a patient with HER2-positive metastatic breast cancer who has previously received multiple lines of therapy, including T-DM1.

Notable Treatment Advances in HER2+ MBC

December 6th 2021

Reactions to presentations from ESMO 2021 that demonstrated the potential of various new treatment approaches for use in HER2-positive metastatic breast cancer.

Implications of HER2CLIMB Updates on Treating HER2+ MBC

December 6th 2021

Key takeaways from updates to the HER2CLIMB study in HER2-positive metastatic breast cancer.